NextPlat Corp. (NASDAQ: NXPL, NXPLW), a global consumer products and services company, reported third-quarter 2026 financial results that highlighted a significant improvement in profitability despite a decline in revenue. The company's net loss attributable to common stockholders narrowed by 66% to approximately $700,000, or $0.28 per diluted share, compared with $2.2 million, or $0.84 per diluted share, in the prior-year period. This reduction in losses came even as revenue fell to approximately $10.5 million from $13.8 million, a decline attributed to lower pharmacy reimbursement rates and retail prescription volumes.
The most notable metric was the expansion of gross margin to approximately 35% from 19.9% a year earlier. This improvement underscores a strategic shift toward higher-margin services, particularly within the company's healthcare operations. Pharmacy contract revenue surged 300% to approximately $2.4 million, driven by growth in 340B services, which are designed to help healthcare providers stretch scarce federal resources. Meanwhile, e-commerce revenue rose 3% to approximately $3.8 million, providing a stable base amid the pharmacy headwinds.
NextPlat's balance sheet remains solid, with approximately $11.2 million in cash and $13.5 million in working capital, and no material unsecured debt. This financial flexibility supports the company's ongoing expansion in the healthcare sector. During the quarter, NextPlat acquired Scott's Pharmacy near Pensacola, Florida, and opened a new location in Jacksonville. These moves are part of a broader effort to build a larger pharmacy network and capture additional market share.
Looking ahead, the company plans to launch a nationwide medication fulfillment website in the fourth quarter, offering consumers across all 50 states online access to prescription and over-the-counter healthcare products. Management expects contributions from the expanded pharmacy network and new contracted services to drive future growth. For investors seeking detailed information, the full press release is available at https://ibn.fm/8alUs, and ongoing updates can be found in the company's newsroom at https://ibn.fm/NXPL.
The implications of these results are significant for NextPlat's trajectory. The sharp reduction in net loss and margin expansion indicate that the company's focus on higher-margin healthcare services is paying off, potentially positioning it for sustained profitability. The 300% growth in pharmacy contract revenue highlights the scalability of the 340B segment, which could become a key driver of future earnings. Additionally, the planned nationwide fulfillment website represents a major step in expanding direct-to-consumer reach, which could diversify revenue streams and reduce reliance on traditional pharmacy reimbursements.
For stakeholders, the solid cash position and absence of material unsecured debt provide a cushion to execute growth initiatives. However, the revenue decline serves as a reminder of the challenges in the pharmacy sector, where reimbursement pressures persist. NextPlat's ability to continue expanding margins while integrating recent acquisitions will be crucial. The company's news is distributed through InvestorWire, a specialized communications platform, and is part of the Dynamic Brand Portfolio at IBN, which provides editorial syndication to 5,000+ outlets and other corporate communications solutions. As NextPlat continues to navigate the evolving healthcare landscape, its Q3 performance offers a glimpse of potential upside if it can maintain momentum in high-margin services and successfully launch its national fulfillment platform.
